Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
EBS is in the long-term up 95% in 3 years.
Description: Emergent BioSolutions Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. The Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine) for the treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F, or G; Vaccinia Immune Globulin Intravenous for counteracting complications associated with the smallpox vaccine; and RSDL (decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. This segment is also developing Anthrax Immune Globulin Intravenous to treat toxemia associated with inhalational anthrax; NuThrax, an anthrax vaccine in Phase II clinical trials, which is based on BioThrax combined with CPG 7909, an adjuvant licensed from Pfizer Inc.; an
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-42.32%||Sales Growth - Q/Q||-57%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||3.86%||ROE||6.59%||ROI||4.26%|
|Current Ratio||5.05||Quick Ratio||4.03||Long Term Debt/Equity||0.77||Debt Ratio||0.15|
|Gross Margin||74.31%||Operating Margin||12%||Net Profit Margin||7.71%||Dividend Payout Ratio|
|Cash From Financing Activities||11 M||Cash From Investing Activities||-9.08 M||Cash From Operating Activities||-65.87 M||Gross Profit||44.88 M|
|Net Profit||-21.52 M||Operating Profit||-28.31 M||Total Assets||917.85 M||Total Current Assets||405.81 M|
|Total Current Liabilities||80.3 M||Total Debt||251 M||Total Liabilities||379.97 M||Total Revenue||63.63 M|
|High 52 week||73.24||Low 52 week||42.42||Last close||58.59||Last change||-3.73%|
|RSI||17.18||Average true range||3.15||Beta||0.82||Volume||333.02 K|
|Simple moving average 20 days||-12.99%||Simple moving average 50 days||-10.21%||Simple moving average 200 days||1.34%|
|Performance Week||-9.28%||Performance Month||-17.79%||Performance Quart||-11.63%||Performance Half||9.25%|
|Performance Year||26.93%||Performance Year-to-date||26.08%||Volatility daily||2.45%||Volatility weekly||5.49%|
|Volatility monthly||11.25%||Volatility yearly||38.96%||Relative Volume||180.22%||Average Volume||401.43 K|
|New High||New Low|
2019-06-15 08:07:01 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-06-14 14:27:22 | Before You Buy Emergent BioSolutions Inc. NYSE:EBS, Consider Its Volatility
2019-06-10 08:07:19 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-06-05 13:20:58 | Emergent BioSolutions CEO on fighting drug pricing and the opioid epidemic
2019-06-04 18:58:00 | Don't Get Complacent: Cramer's 'Mad Money' Recap Tuesday 6/4/19
2019-06-04 11:52:03 | Emergent EBS Wins HHS Contract to Supply VIGIV Product
2019-06-04 08:06:06 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-06-03 14:53:59 | What Emergent’s latest $535M contract means for national ‘smallpox franchise’
2019-06-01 09:31:01 | Why Is Emergent Biosolutions EBS Down 23.4% Since Last Earnings Report?
2019-05-30 08:07:07 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-05-23 07:15:36 | You Might Like Emergent BioSolutions Inc. NYSE:EBS But Do You Like Its Debt?
2019-05-21 09:22:30 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-05-20 06:30:00 | Emergent BioSolutions to Participate in Series of Investor Conferences
2019-05-15 08:15:00 | 3 Top Healthcare Stocks to Buy in May
2019-05-14 11:47:47 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-05-08 16:54:00 | Emergent BioSolutions Negotiates for a Strong Second Half
2019-05-07 06:00:00 | 3 Top Biotech Stocks to Buy in May
2019-05-03 15:41:07 | Emergent EBS Earnings & Revenues Miss Estimates in Q1
2019-05-03 15:07:00 | Why Emergent BioSolutions Stock Is Tanking Today
2019-05-03 08:14:53 | Emergent BioSolutions Inc EBS Q1 2019 Earnings Call Transcript
2019-05-03 07:38:11 | New Strong Sell Stocks for May 3rd
2019-05-03 01:07:37 | Edited Transcript of EBS earnings conference call or presentation 2-May-19 9:00pm GMT
2019-05-02 19:25:11 | Emergent Biosolutions EBS Reports Q1 Loss, Misses Revenue Estimates
2019-05-02 18:18:30 | Emergent Biosolutions: 1Q Earnings Snapshot
2019-05-02 16:05:00 | Emergent BioSolutions Reports First Quarter 2019 Financial Results
2019-04-26 11:51:19 | Is Emergent Biosolutions Inc EBS A Good Stock To Buy ?
2019-04-25 10:34:02 | Emergent Biosolutions EBS Reports Next Week: Wall Street Expects Earnings Growth
2019-04-19 12:04:00 | FDA approves first generic naloxone nasal spray to treat opioid overdose
2019-04-17 11:01:03 | Emergent's EBS Chikungunya Vaccine Positive in Phase II Study
2019-04-09 10:59:02 | Emergent's EBS Strong Vaccine Portfolio to Fuel Growth
2019-04-09 10:50:40 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-03-26 08:24:25 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-03-23 09:30:01 | Emergent Biosolutions EBS Down 24.2% Since Last Earnings Report: Can It Rebound?
2019-03-20 11:24:03 | Emergent Begins Phase III Study on Anthrax Vaccine AV7909
2019-03-14 11:21:02 | Life Sciences Pa. reveals awards for its top CEO, top products and deal of the year
2019-02-25 16:20:00 | Emergent BioSolutions Looks to Break $1 Billion
2019-02-22 21:48:03 | Emergent BioSolutions Inc EBS Files 10-K for the Fiscal Year Ended on December 31, 2018
2019-02-22 15:42:04 | Edited Transcript of EBS earnings conference call or presentation 21-Feb-19 10:00pm GMT